Business Context and Reporting Period
Clover Health Investments, Corp. filed its Form 10-K for the fiscal year ended December 31, 2020. The filing is primarily the audited financial report of Social Capital Hedosophia Holdings Corp. III, the former special purpose acquisition company, because the Business Combination with Clover Health closed on January 7, 2021. Before closing, the registrant had no operating business or revenue and conducted only formation, initial public offering, and merger-related activities.
The operating financial statements of Clover Health, the accounting predecessor, were expected to be filed separately in an amendment to Form 8-K. Accordingly, the financial metrics in this 10-K should not be interpreted as the consolidated operating results of the healthcare business.
Key Financial Metrics
| Metric | Year ended December 31, 2020 | Comparable 2019 period |
|---|---|---|
| Revenue | $0 | $0 |
| Formation and operating costs | $6.9 million | $17,631 |
| Interest income | $117,255 | $0 |
| Net loss | $6.7 million | $17,631 |
| Net cash used in operating activities | $2.2 million | $17,631 |
| Cash and marketable securities in Trust Account | $828.1 million | Not applicable |
| Cash outside Trust Account | $28.0 million | $0 |
| Total assets | $856.4 million | $100,346 |
| Total liabilities | $62.9 million | $117,977 |
| Class A shares subject to possible redemption | $788.5 million | $0 |
The filing does not provide meaningful revenue, operating margin, medical cost ratio, healthcare cash flow, or consolidated debt metrics for Clover Health’s insurance operations. The SPAC reported no revenue and had no long-term debt, capital leases, operating leases, or other long-term liabilities as of December 31, 2020. A related-party promissory note had an outstanding balance of $806,208 at year-end and was repaid at the Business Combination closing.
Material Changes Versus the Prior Comparable Period
- The company completed its initial public offering on April 24, 2020, selling 82.8 million units at $10 per unit and generating gross proceeds of $828.0 million.
- The company sold 10.9 million private placement warrants for $16.4 million.
- Cash and marketable securities increased to $856.4 million in total assets from $100,346 at December 31, 2019, primarily because of the IPO and related financing activities.
- Net loss increased to $6.7 million from $17,631 because of public-company, offering, due-diligence, and merger-related costs.
- On January 7, 2021, the company completed the Domestication, Mergers, and name change to Clover Health Investments, Corp. The company also completed a $400 million PIPE investment, issued approximately 40 million Class A shares, and paid $499.8 million of cash merger consideration.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no formal operating or financial guidance for the combined Clover Health business.
- Management described a post-closing strategy centered on Medicare Advantage plans, the Clover Assistant technology platform, geographic expansion, and participation in the CMS Direct Contracting model, planned to begin in April 2021.
- The filing separately reports that Clover Health, the operating predecessor, incurred net losses of $136.4 million in 2020 and $363.7 million in 2019, with negative operating cash flow. These figures are risk-factor disclosures and are not included in the audited SPAC financial statements presented in this 10-K.
- Key operating risks include continued losses, increased investment requirements, medical-cost and incurred-but-not-reported claims estimation, CMS risk-adjustment and retroactive payment changes, Medicare regulation, statutory capital requirements, COVID-19 effects, provider and member concentration, and execution risk associated with Clover Assistant adoption.
- Approximately 96% of Clover’s members were residents of New Jersey as of December 31, 2020, creating geographic concentration risk. Clover reported a 3.0 CMS Star Rating for 2020.
- The company disclosed an SEC subpoena received in February 2021 concerning aspects of its business and matters discussed in a Hindenburg Research article. It also disclosed related securities class actions and a derivative action filed in February 2021. The matters were in preliminary stages, and no loss amount could be estimated.
- A material weakness was identified in internal control over financial reporting relating to the valuation of an embedded derivative in Clover’s convertible securities. The derivative liability should have been $44.8 million but was initially recorded at zero, increasing reported net loss by $44.8 million versus the prior earnings release. Management stated the weakness was remediated when the derivative was extinguished upon closing of the Business Combination.
- The dual-class structure gives Class B common stock ten votes per share. Directors, officers, principal stockholders, and affiliates held approximately 72.9% of total voting power as of January 7, 2021.
- The company does not expect to pay cash dividends in the foreseeable future.
Most Important Facts for Investors to Verify
- Confirm that the financial statements in this filing represent the former SPAC and do not include Clover Health’s operating results.
- Review the separate Clover Health predecessor financial statements and the post-merger Form 8-K for revenue, membership, medical cost ratio, liquidity, statutory capital, debt, and operating cash flow.
- Assess the impact of the $44.8 million derivative-accounting correction and the remediation of the related material weakness.
- Monitor the SEC investigation, U.S. Attorney inquiry, securities class actions, derivative litigation, and any related reserves or settlements.
- Evaluate CMS risk-adjustment settlements, Star Ratings, medical-cost trends, COVID-19 deferred care, and the company’s ability to maintain required insurance subsidiary capital.
- Assess dilution and governance implications from the PIPE shares, Class B voting control, outstanding options and RSUs, and approximately 38.5 million warrants exercisable at $11.50 per share.